COMMUNIQUÉS West-GlobeNewswire

The Hydropothecary Corporation Announces Graduation to the TSX, Shareholder Meeting for Rebranding to HEXO
21/06/2018
GATINEAU, Quebec, June 21, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“THCX” or the “Company”) (TSX-V:THCX) announced today that it has received approval from the Toronto Stock Exchange (the “TSX”) to [...]
Inscription de la société Hydropothecary à la TSX et assemblée des actionnaires concernant la nouvelle marque HEXO
21/06/2018
GATINEAU, Québec, 21 juin 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (« THCX » ou la « Société ») (TSX-V:THCX) a annoncé aujourd’hui qu’elle a reçu l’approbation de la Bourse de Toronto (la « TSX ») lui [...]
Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting
21/06/2018
NEW YORK and MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic [...]
Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine
21/06/2018
SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: [...]
Wright Medical Group N.V. Announces Private Placement of $675 Million of 1.625% Cash Convertible Senior Notes Due 2023
21/06/2018
AMSTERDAM, The Netherlands, June 21, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) (the “Company”) today announced that it has entered into privately negotiated agreements among the Company, Wright [...]
PotNetwork Holdings, Inc.’s Diamond CBD Continues Surpassing $2 Million In Sales Per Month Practically Doubling Revenues Year Over Year
21/06/2018
Diamond CBD keeps breaking previous year’s records with May 2018 Sales FT LAUDERDALE, Fla., June 21, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork Holdings, Inc. (OTC Pink:POTN) is pleased to announce that its [...]
ViroGates’ initial public offering of new shares was 141% oversubscribed
21/06/2018
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. This announcement does not constitute a prospectus. No one [...]
Enrollment of first patient in Phase II clinical trial for Gaucher disease
21/06/2018
Orphazyme A/S Company announcement No. 08/2018 Company Registration No. 32266355 Copenhagen, June 21, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare [...]
Shire Announces FDA Approval for Label Expansion of CINRYZE® for Prevention of Attacks in Pediatric HAE
21/06/2018
Shire Announces FDA Approval for Label Expansion of CINRYZE ® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients CINRYZE is the first and only therapy indicated in the [...]
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
21/06/2018
Press release Leuven, Belgium, 21 June 2018 - ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic [...]
Bone Therapeutics SA: The preliminary documents for the Extraordinary General Shareholder Meeting on 9 July 2018 have been made available
21/06/2018
Regulated information The preliminary documents for the Extraordinary General Shareholder Meeting on 9 July 2018 have been made available Gosselies, Belgium, 21 June 2018, 7am CEST - BONE THERAPEUTICS (Euronext Brussels [...]
Bone Therapeutics SA : Mise à disposition des documents préparatoires à l'assemblée générale extraordinaire du 9 juillet 2018
21/06/2018
Information réglementée Mise à disposition des documents préparatoires à l'assemblée générale extraordinaire du 9 juillet 2018 Gosselies, Belgique, le 21 juin 2018, 7h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
21/06/2018
Geneva, Switzerland, 21 June 2018 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved all the [...]
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
21/06/2018
BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic [...]
AVROBIO, Inc. Announces Pricing of Initial Public Offering
21/06/2018
CAMBRIDGE, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to [...]
Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
21/06/2018
CHICAGO, June 20, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and [...]
Two Publications Recognize NovuHealth as a Top Workplace in Minnesota
20/06/2018
The Star Tribune and Minneapolis/St. Paul Business Journal Both Include NovuHealth on Their Lists for 2018 MINNEAPOLIS, June 20, 2018 (GLOBE NEWSWIRE) -- NovuHealth , the healthcare industry’s leading consumer [...]
Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stock
20/06/2018
CRANBURY, N.J., June 20, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and [...]
Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt
20/06/2018
IRVING, Texas, June 20, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of Reata’s RTA 1701, a [...]

Pages